Apr. 20 at 6:35 PM
$CLRB was off for a while (besides every once in a while when some financial guru comes out spreading illogical finance stuff, lol). I am more confident than ever, while keeping in mind that this is by far and IMO, as any biotech stock, a volatile and risky financial investment. That said, I believe that:
- insiders and management are IMO good with the current capital structure of the stock right now, included stock options;
- IMO they should have raised cash in January in the normal operational way of business and if they decided not to is because they were quite confident that a partnership would hit in the following months;
- is there any risk of heavy dilution? Yes, if a deal doens't materialize for whatever reason, they could dilute highly to stay in business untill a partnership will hit, if ever.
My conclusion is that:
- they will present 12m data of 131 at ASCO;
- a partnership will be announced before next e.r. and, IMO, even as soon as the coming days.
These my 2 cents.
